Direct answer: regulatory strategy should start at the idea stage, not after you build a prototype.
If you wait until the device is engineered to think about FDA requirements, you’ve already made decisions that may be expensive—or impossible—to fix later.
Why Regulatory Strategy Starts at Ideation
From the very beginning, the U.S. Food and Drug Administration does not look at your device as “cool technology.”
They look at it as a risk-control system meant to protect patients.
That perspective affects early decisions more than most founders realize.
1. Intended Use Drives the Entire Regulatory Path
Your intended use determines:
Device classification (Class I, II, or III)
Whether you need a 510(k), De Novo, or PMA
The type and amount of evidence FDA will expect
Even small wording choices can push your device into a higher-risk category. Changing intended use later often means repeating testing or restarting the regulatory process entirely.
This is why intended use should be pressure-tested before design begins—not after.
2. Design Choices Are Regulatory Choices
Early design decisions have regulatory consequences, whether you plan for them or not:
Materials affect biocompatibility testing
Software functions affect software level of concern
User population affects human factors requirements
Connectivity affects cybersecurity expectations
When these issues are ignored early, engineering teams often design devices that work technically—but are difficult to justify from a regulatory standpoint.
3. Evidence Cannot Be Added After the Fact
FDA expects safety and performance evidence to be:
Planned in advance
Linked to identified risks
Traceable to design inputs
Trying to “add” regulatory evidence after a prototype is built often leads to:
Redundant or invalid studies
Data FDA will not accept
Costly delays and redesigns
If evidence planning is not built in early, you are setting yourself up for rework.
Where Kandih Comes In
This is where Kandih Group supports founders best—before engineering decisions harden.
Kandih helps innovators:
Pressure-test device ideas against FDA expectations
Clarify intended use without triggering regulatory creep
Identify regulatory risks tied to materials, software, and use
Build an evidence strategy that aligns with FDA standards
Avoid redesigns, repeat testing, and wasted capital
In short: we help you design with the FDA in mind, instead of defending decisions later.
Bottom Line
Regulatory strategy is not a final step.
It is a design input.
Starting regulatory strategy at ideation:
Saves time
Saves money
Reduces regulatory risk
Increases the chance your device reaches patients
If speed matters, start early. If success matters, start smart.
References
FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
FDA – Quality System Regulation (21 CFR Part 820)
https://www.fda.gov/medical-devices/quality-system-qs-regulation-medical-device/current-good-manufacturing-practice-cgmp
FDA – Design Controls Guidance for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices
FDA – Recognized Consensus Standards (ISO 14971 Risk Management)
https://www.fda.gov/medical-devices/standards-and-conformity-assessment-program/recognized-consensus-standards